|
|
||||||||||||||
|
|
|||||||||||||||
REVIEW |
1 Institute of Science and Technology in Medicine, Keele University, Hartshill, UK
2 Keele University School of Medicine, Hartshill, UK
Correspondence to:
Correspondence to:
N Maffulli
Keele University School of Medicine, Hartshill, UK;osa14{at}keele.ac.uk
ABSTRACT
Tissue engineering aims to induce tissue self-regeneration in vivo or to produce a functional tissue replacement in vitro to be then implanted in the body. To produce a viable and functional tendon, a uniaxially orientated collagen type I matrix has to be generated. Biochemical and physical factors can potentially alter both the production and the organisation of this matrix, and their combination in a dose- and time-dependent manner is probably the key to in vitro engineered tendons. This review discusses the role of these different factors affecting tenocyte growth in a three-dimensional environment in vivo and in vitro, and underlines the future challenge of tendon tissue engineering.
Abbreviations: bFGF, basic fibroblast growth factor; BMP, bone morphogenetic protein; ECM, extracellular matrix; MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor
3 International Neuroscience Institute, Orthopaedic Surgery, Sports Traumatology, Hannover, Germany; office{at}bosch-ini-hannover.de
This article has been cited by other articles:
![]() |
N. Maffulli and U. G. Longo Conservative management for tendinopathy: is there enough scientific evidence? Rheumatology, April 1, 2008; 47(4): 390 - 391. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |